Over-expression of LRIG3 suppresses growth and invasion of bladder cancer cells

Abstract

The purpose of this study was to investigate the impact of leucine-rich repeats and immunoglobulin-like domains 3 (LRIG3) on the biological features of bladder cancer cell lines. The plasmids of over-expressed LRIG3 and the blank plasmid serving as control were transfected into the bladder cancer cell lines, T24, EJ and BIU-87, and the expression levels of LRIG3 mRNA and protein were detected by using real-time PCR and Western blotting. The changes in the cell cycle and apoptosis were examined by using flow cytometry. The invasive ability was measured by Transwell assay, and CCK-8 assays were used to measure the proliferation of cells. As compared with the control group, the LRIG3 mRNA and protein expression levels in LRIG3 cDNA-transfected group were raised significantly (P<0.05). The average number of cells with up-regulated LRIG3 passing through the inserted filter was decreased significantly as compared with the control group (P<0.05). Up-regulation of LRIG3 also could inhibit proliferation and induce apoptosis of T24, EJ and BIU-87 cells. Except BIU-87, the T24 and EJ cells transfected with LIRG3 cDNA were arrested in G₀/G₁ phase compared to the control group (P<0.05). In conclusion, the over-expression of LRIG3 could influence the cell cycle and invasion, inhibit proliferation and induce apoptosis in the three bladder cancer cell lines.

Keywords

LRIG3 / bladder cancer cell lines / cell cycle / apoptosis / invasion

References

[1] JemalA., SiegelR., WardE., et al.. Cancer statistics, 2008. CA Cancer J Clin, 2008, 58(2): 71-96

[2] NilssonJ., VallboC., GuoD., et al.. Cloning, characterization, and expression of human LIG1. Biochem Biophys Res Commun, 2001, 284(5): 1155-1161

[3] HolmlundC., NilssonJ., GuoD., et al.. Characterization and tissue-specific expression of human LRIG2. Gene, 2004, 332(12): 35-43

[4] GuoD., HolmlundC., HenrikssonR., et al.. The LRIG gene family has three vertebrate paralogs widely expressed in human and mouse tissues and a homolog in Ascidiacea. Genomics, 2004, 84(1): 157-165

[5] LaederichM.B., Funes-DuranM., YenL., et al.. The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases. J Biol Chem, 2004, 279(45): 47 050-47 056

[6] GurG., RubinC., KatzM., et al.. LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation. EMBO J, 2004, 23(16): 3270-3281

[7] ShattuckD.L., MillerJ.K., LaederichM., et al.. LRIG1 is a novel negative regulator of the Met receptor and opposes Met and Her2 synergy. Mol Cell Biol, 2007, 27(5): 1934-1946

[8] ReifenbergerG., IchimuraK., ReifenbergerJ., et al.. Refined mapping of 12q13-q15 amplicons in human malignant gliomas suggests CDK4/SAS and MDM2 as independent amplification targets. Cancer Res, 1996, 56(22): 5141-5145

[9] HedmanH., NilssonJ., GuoD., et al.. Is LRIG1 a tumour suppressor gene at chromosome 3p14.3. Acta Oncol, 2002, 41(4): 352-354

[10] CaiM., HanL., ChenR., et al.. Inhibition of LRIG3 gene expression via RNA interference modulates the proliferation, cell cycle, cell apoptosis, adhesion and invasion of glioblastoma cell (GL15). Cancer Lett, 2009, 278(1): 104-112

[11] KatayamaM., SanzenN., FunakoshiA., et al.. Laminin gamma2-chain fragment in the circulation: a prognostic indicator of epithelial tumor invasion. Cancer Res, 2003, 63(1): 222-229

[12] WernickeM., PineiroL.C., CaramuttiD., et al.. Breast cancer stromal myxoid changes are associated with tumor invasion and metastasis: a central role for hyaluronan. Mod Pathol, 2003, 16(2): 99-107

[13] KurokawaH., KatsubeK., PodymaK.A., et al.. Heparanase and tumor invasion patterns in human oral squamous cell carcinoma xenografts. Cancer Sci, 2003, 94(3): 277-285

[14] YardenY.. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer, 2001, 37(Suppl4): S3-8

[15] PedersenM.W., MeltornM., DamstrupL., et al.. The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy. Ann Oncol, 2001, 12(6): 745-760

[16] LjungbergB., GafvelsM., DamberJ.E.. Epidermal growth factor receptor gene expression and binding capacity in renal cell carcinoma, in relation to tumor stage, grade and DNA ploidy. Urol Res, 1994, 22(5): 305-308

[17] YeF., GaoQ., XuT., et al.. Upregulation of LRIG1 suppresses malignant glioma cell growth by attenuating EGFR activity. J Neurooncol, 2009, 94(2): 183-194

[18] LiF., YeZ.Q., GuoD.S., et al.. Suppression of bladder cancer cell tumorigenicity in an athymic mouse model by adenoviral vector-mediated transfer of LRIG1. Oncol Rep, 2011, 26(2): 439-446